ArticleOncology letters2026
Accuracy of percutaneous ultrasound-guided needle biopsy of abdominal lymph nodes for the diagnosis of malignant disease.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The differential diagnosis of suspected neoplastic disease involving deep lymph nodes remains challenging, particularly in the abdomen, where biopsies are technically more complex and associated with higher procedural risks. The present retrospective single-center study aimed to evaluate the feasibility, safety and diagnostic accuracy of ultrasound-guided needle biopsy in patients with neoplastic disease of deep abdominal lymph nodes. A total of 77 abdominal lymph node biopsies were analyzed. Among them, 15 (19.5%) were non-diagnostic. Of the remaining 62 diagnostic biopsies, 40 (64.5%) were lymphomas, 17 (27.4%) were solid tumors, and 5 (8.1%) were non-neoplastic conditions. Among the 57 biopsies positive for neoplastic disease, 32 of 40 (80.0%) lymphomas and six of 17 (35.3%) solid tumors represented new diagnoses, while the remaining cases were histologically confirmed. No procedure-related adverse events were observed. The sensitivity, specificity, positive predictive value and negative predictive value were 100, 83.3, 98.2 and 100%, respectively. The overall diagnostic yield was 80.5%, and the diagnostic accuracy reached 98.4%. US-NB could represent an accurate and reliable diagnostic tool for evaluating suspected neoplastic disease of deep abdominal lymph nodes, both at initial diagnosis and at relapse, offering a favorable safety profile and high diagnostic performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.